Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987

Joaquim Bellmunt; Hans von der Maase; Graham M Mead; Iwona Skoneczna; Maria De Santis; Gedske Daugaard; Andreas Boehle; Christine Chevreau; Luis Paz-Ares; Leslie R Laufman; Eric Winquist; Derek Raghavan; Sandrine Marreaud; Sandra Collette; Richard Sylvester; Ronald de Wit

doi:10.1200/JCO.2011.38.6979

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987

Joaquim Bellmunt, Hans von der Maase, Graham M Mead, Iwona Skoneczna, Maria De Santis, Gedske Daugaard, Andreas Boehle, Christine Chevreau, Luis Paz-Ares, Leslie R Laufman, Eric Winquist, Derek Raghavan, Sandrine Marreaud, Sandra Collette, Richard Sylvester, Ronald de Wit

396 Citationer (Scopus)

Abstract

The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor activity and might improve survival.

Originalsprog	Engelsk
Tidsskrift	Journal of Clinical Oncology
Vol/bind	30
Udgave nummer	10
Sider (fra-til)	1107-13
Antal sider	7
ISSN	0732-183X
DOI	https://doi.org/10.1200/JCO.2011.38.6979
Status	Udgivet - 2012

Adgang til dokumentet

10.1200/JCO.2011.38.6979

Andre filer og links

Link to publication in Scopus

Fingeraftryk

Dyk ned i forskningsemnerne om 'Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Bellmunt, J., von der Maase, H., Mead, G. M., Skoneczna, I., De Santis, M., Daugaard, G., Boehle, A., Chevreau, C., Paz-Ares, L., Laufman, L. R., Winquist, E., Raghavan, D., Marreaud, S., Collette, S., Sylvester, R., & de Wit, R. (2012). Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. Journal of Clinical Oncology, 30(10), 1107-13. https://doi.org/10.1200/JCO.2011.38.6979

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. / Bellmunt, Joaquim; von der Maase, Hans; Mead, Graham M et al.
I: Journal of Clinical Oncology, Bind 30, Nr. 10, 2012, s. 1107-13.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Bellmunt, J, von der Maase, H, Mead, GM, Skoneczna, I, De Santis, M, Daugaard, G, Boehle, A, Chevreau, C, Paz-Ares, L, Laufman, LR, Winquist, E, Raghavan, D, Marreaud, S, Collette, S, Sylvester, R & de Wit, R 2012, 'Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987', Journal of Clinical Oncology, bind 30, nr. 10, s. 1107-13. https://doi.org/10.1200/JCO.2011.38.6979

Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. Journal of Clinical Oncology. 2012;30(10):1107-13. doi: 10.1200/JCO.2011.38.6979

@article{fec3cbb919ec4728b0b10beb92a30330,

title = "Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987",

abstract = "The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor activity and might improve survival.",

keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Cisplatin, Deoxycytidine, Disease-Free Survival, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Neutropenia, Paclitaxel, Survival Analysis, Thrombocytopenia, Treatment Outcome, Urologic Neoplasms, Urothelium",

author = "Joaquim Bellmunt and \{von der Maase\}, Hans and Mead, \{Graham M\} and Iwona Skoneczna and \{De Santis\}, Maria and Gedske Daugaard and Andreas Boehle and Christine Chevreau and Luis Paz-Ares and Laufman, \{Leslie R\} and Eric Winquist and Derek Raghavan and Sandrine Marreaud and Sandra Collette and Richard Sylvester and \{de Wit\}, Ronald",

year = "2012",

doi = "10.1200/JCO.2011.38.6979",

language = "English",

volume = "30",

pages = "1107--13",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy

T2 - EORTC Intergroup Study 30987

AU - Bellmunt, Joaquim

AU - von der Maase, Hans

AU - Mead, Graham M

AU - Skoneczna, Iwona

AU - De Santis, Maria

AU - Daugaard, Gedske

AU - Boehle, Andreas

AU - Chevreau, Christine

AU - Paz-Ares, Luis

AU - Laufman, Leslie R

AU - Winquist, Eric

AU - Raghavan, Derek

AU - Marreaud, Sandrine

AU - Collette, Sandra

AU - Sylvester, Richard

AU - de Wit, Ronald

PY - 2012

Y1 - 2012

N2 - The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor activity and might improve survival.

AB - The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor activity and might improve survival.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carcinoma, Transitional Cell

KW - Cisplatin

KW - Deoxycytidine

KW - Disease-Free Survival

KW - Drug Administration Schedule

KW - Female

KW - Hemorrhage

KW - Humans

KW - Male

KW - Middle Aged

KW - Neutropenia

KW - Paclitaxel

KW - Survival Analysis

KW - Thrombocytopenia

KW - Treatment Outcome

KW - Urologic Neoplasms

KW - Urothelium

UR - https://www.scopus.com/pages/publications/84863897662

U2 - 10.1200/JCO.2011.38.6979

DO - 10.1200/JCO.2011.38.6979

M3 - Journal article

C2 - 22370319

SN - 0732-183X

VL - 30

SP - 1107

EP - 1113

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 10

ER -